secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2023-01-31T23:59:59+00:00
Accession:  0000950170-23-001502
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences announces 1-for-35 reverse stock split effective Feb 1, 2023
--------------------------------------------------------------------------------

- Reverse split reduces outstanding shares from ~23.5M to ~672,460 shares.
- Authorized common stock increased from 100M to 500M shares via charter amendment.
- Split intended to regain Nasdaq minimum bid compliance; new CUSIP 76135L 309.
- Stockholders also ratified Baker Tilly US, LLP as auditor for FY 2023.
- Proportionate adjustments applied to warrants, options, and equity awards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023001502/0000950170-23-001502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023001502/revb-20230130.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-001502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer